CSL has always traded at a premium. This premium is beginning to unwind. CSL has produced single digit growth in earnings which does not justify investors paying a multiple of 40 PE. The premium has been paid for the blue sky that the R&D pipeline has promised to deliver. The problem is that CSL will be busy producing vaccines at cost price with no profit. That’s the price CSL had to pay for the Federal government to cover some of the capital costs in building new facilities. And more government intervention is never a good thing for investors. Hence, the sell off and rotation out of healthcare.
CSL possible pull back to low $200's, page-223
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.14 |
Change
-3.850(1.27%) |
Mkt cap ! $145.2B | |||
| Open | High | Low | Value | Volume |
| $298.10 | $300.96 | $298.10 | $53.05M | 181.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 24 | $300.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.14 | 26 | 3 |
View Market Depth
| Last trade - 12.36pm 09/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |